News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nerviano Medical Sciences (NervianoMS) and Servier Announce a Collaboration and License Agreement for a Novel Anticancer Drug


7/30/2013 9:26:41 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NERVIANO, Italy & SURESNES, France--(BUSINESS WIRE)--Nerviano Medical Sciences, the largest pharmaceutical R&D facility in Italy, one of the leading oncology-focused, integrated discovery and development companies in Europe, and Servier, a leading research-based European pharmaceutical company today announced a collaboration and worldwide license agreement to further develop and commercialize first-in-class Nerviano compounds inhibiting the protein kinase TTK/MPS1. A key regulator of mitosis TTK/MPS1 is aberrantly overexpressed in a wide range of tumours and represents a promising target in oncology.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES